Tirzepatide
Dual-action metabolic therapy.
A medically-supervised therapy for adults pursuing meaningful changes in body composition and glycemic control — engineered with dual incretin 2.5 5 7.5 10 12.
A new class of metabolic medicine.
A dual GIP and GLP-1 receptor agonist engaging both incretin pathways simultaneously — addressing insulin, glucagon, appetite, and gastric emptying in one therapy.
- Adults pursuing meaningful weight reduction
- Patients managing type 2 diabetes or metabolic syndrome
- Anyone whose body composition has plateaued
Enhanced Glycemic Control
Glucose-dependent insulin secretion and reduced glucagon output. Blood sugar stays more stable through the day.
Significant Weight Reduction
Dual receptor activity suppresses appetite and supports energy use. Appetite quiets and portions feel naturally smaller.
Metabolic Cardiovascular Support
Sustained weight loss may improve lipid and blood-pressure markers. Important metabolic numbers often trend favorably.
Once-Weekly Convenience
A single subcutaneous injection supports long-term adherence. One weekly injection — easy to keep up with consistently.
Application Beyond Diabetes
Increasingly used by adults pursuing weight reduction alone. Used by adults without diabetes for body composition.
Appetite changes emerge; mild GI adjustment.
Visible weight loss begins; energy stabilizes.
Substantial body composition changes emerge.
- Physician-supervised by Thomas Nabity, MD
- 503A / 503B compounding pharmacy sourcing
- Pre-protocol labs, body composition, and review
- 30 / 60 / 90-day follow-up with companion support